|
KMID : 1141520190340010053
|
|
Endocrinology and Metabolism
2019 Volume.34 No. 1 p.53 ~ p.62
|
|
|
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
|
|
Chin Sang-Ouk
Ku Cheol-Ryong
Kim Byung-Joon
Kim Sung-Woon
Park Kyeong-Hye
Song Kee-Ho
Oh Seung-Joon
Yoon Hyun-Koo
Lee Eun-Jig
Lee Jung-Min
Lim Jung-Soo
Kim Jung-Hee
Kim Kwang-Joon
Jin Heung-Yong
Kim Dae-Jung
Lee Kyung-Ae
Moon Seong-Su
Lim Dong-Jun
Shin Dong-Yeob
Kim Se-Hwa
Kwon Min-Jeong
Kim Ha-Young
Kim Jin-Hwa
Kim Dong-Sun
Kim Chong-Hwa
|
|
|
Abstract
|
|
|
|
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
|
|
|
KEYWORD
|
|
|
Acromegaly, Somatostatin analogues, Octreotide, Lanreotide, Pasireotide
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
    
|
|